Healthy Extracts Issues $258,750 Convertible Note with Deeply Discounted Conversion Terms
HYEX is trading near its 52-week low of $0.805 (14% above the low) on light trading volume (0.3× avg).
Summary
Healthy Extracts Inc. entered into a $258,750 convertible note financing with LABRYS FUND II, L.P., receiving $225,000 in net proceeds. The note converts at a variable discount to market after 180 days, creating potential for substantial dilution.
Key Events · Financing and Capital Events · HYEX
-
Convertible Note Issued
Issued a $258,750 promissory note to LABRYS FUND II, L.P. with an original issue discount of $33,750, netting $225,000 after fees. The note bears 10% interest and matures July 17, 2027.
-
Variable Conversion Price
After 180 days, the note converts at the lesser of $2.00 per share or 75% of the lowest closing bid price over the prior 15 trading days. At the current $0.91 stock price, the market-based conversion price could be as low as $0.68, implying up to 380,000 shares if fully converted at that floor.
-
Anti-Dilution Reset
If the company issues securities at a lower effective price, the conversion price resets to that lower price, potentially increasing dilution without any floor.
-
Amortization Payments
Monthly payments of $36,964.28 begin January 18, 2027, totaling $221,785.68 over six months, unless the note is converted earlier.
Analysis · HYEX · Life Sciences
Healthy Extracts raised $225,000 in net proceeds through a convertible note with LABRYS FUND II, L.P. The note carries a 10% interest rate and an original issue discount of $33,750, maturing in one year. After 180 days, the holder can convert at the lesser of $2.00 per share or 75% of the lowest closing bid price over the prior 15 trading days—a structure that can lead to significant dilution if the stock price declines. With the stock currently at $0.91, the market-based conversion floor is already below the $2.00 fixed price, and the anti-dilution provision resets the conversion price to any lower price in future financings. This financing follows two senior executive departures in July and comes amid a cash-constrained environment, suggesting the company is accessing expensive capital to fund operations.
At the time of this filing, HYEX was trading at $0.91 on OTC in the Life Sciences sector, with a market capitalization of approximately $15.4M. The 52-week trading range was $0.81 to $4.29. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.